Navigation Links
Large lung cancer study shows potential for more targeted therapies
Date:9/9/2012

A nationwide consortium of scientists has reported the first comprehensive genetic analysis of squamous cell carcinoma of the lung, a common type of lung cancer responsible for about 400,000 deaths each year.

"We found that almost 75 percent of the patients' cancers have mutations that can be targeted with existing drugs -- drugs that are available commercially or for clinical trials," says one of the lead investigators, Ramaswamy Govindan, MD, an oncologist at Washington University School of Medicine in St. Louis and co-chair of the lung cancer group of The Cancer Genome Atlas.

The research appears online Sept. 9 in Nature.

The Cancer Genome Atlas project combines efforts of the nation's leading genetic sequencing centers, including The Genome Institute at Washington University, to describe the genetics of common tumors with the goal of improving prevention, detection and treatment. The Cancer Genome Atlas is supported by the National Cancer Institute and the National Human Genome Research Institute, both parts of the National Institutes of Health (NIH).

The other lung cancer co-chairs are the study's senior author Matthew Meyerson, MD, PhD, of the Broad Institute of Massachusetts Institute of Technology and Harvard University, and Stephen Baylin, MD, of Johns Hopkins University.

The study examined the tumors and normal tissue of 178 patients with lung squamous cell carcinoma. The investigators found recurring mutations common to many patients in 18 genes. And almost all of the tumors showed mutations in a gene called TP53, known for its role in repairing damaged DNA.

Interestingly, the researchers noted that lung squamous cell carcinoma shares many mutations with head and neck squamous cell carcinomas, supporting the emerging body of evidence that cancers may be more appropriately classified by their genetics rather than the primary organ they affect.

"We clearly see mutations in lung cancer that we see in other human cancers," says Richard K. Wilson, PhD, director of The Genome Institute at Washington University. "This reinforces something that we've been seeing in a lot of our cancer genomics work. It's really less about what type of tissue the tumor arises in lung, breast, skin, prostate and more about what genes and pathways are affected."

Current treatment for squamous cell lung cancers includes chemotherapy and radiation, but there are no drugs specifically designed to target this particular type of lung cancer. Squamous cell lung cancer is linked to smoking and responsible for 30 percent of all lung cancer cases.

"With this analysis, we are just starting to understand the molecular biology of lung squamous cell carcinoma," says Govindan, who treats patients at Siteman Cancer Center at Barnes-Jewish Hospital and Washington University. "And now we have identified potential targets for therapies to study in future clinical trials."


'/>"/>

Contact: Julia Evangelou Strait
straitj@wustl.edu
314-286-0141
Washington University School of Medicine
Source:Eurekalert

Related medicine news :

1. Worlds largest meeting of ear, nose, and throat doctors
2. Fruit flies on methamphetamine die largely as a result of anorexia
3. Men with large waists face an increased risk of frequent urination
4. Obesity in type 2 diabetes: Recommendations from guidelines are largely consistent
5. Human papillomavirus types do not replace others after large-scale vaccination
6. Largest review of management and treatment of Barretts dysplasia and adenocarcinoma
7. HIV suppression not as good as previously thought, largest study of viral-load blood tests show
8. Large Breasts Can Take Mental, Physical Toll on Teens
9. Could a larger waistline be a result of too much TV as a child?
10. Obesity, larger waist size associated with better outcomes in heart failure patients
11. OnPage Provides Secure, Rapid Response at New England’s Largest Catholic Hospital
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... December 07, 2016 , ... ... financial consultation services to residents in the Sacramento/Folsom region, is initiating a charity ... facility. , The Another Choice Another Chance treatment center in Sacramento works to ...
(Date:12/7/2016)... ... December 07, 2016 , ... A. Kevin Spann Insurance, ... families throughout the Five Boroughs, is launching a charity drive to raise funds that ... the traditions and spirit of marines and Navy FMF Corpsmen. Working closely with the ...
(Date:12/7/2016)... ... December 07, 2016 , ... Facial plastic surgeon, Dr. John D. Rachel ... a portion of proceeds to two local organizations: North Chicago Animal Control and Friends ... is a team of authorized and trained volunteers who support rescued animals held ...
(Date:12/7/2016)... ... December 07, 2016 , ... The medical profession is well aware that heart ... major study analyzing heart attacks among 138,602 people recorded a 35% higher number of ... would all agree of course–no time of year is a good time for a ...
(Date:12/7/2016)... Norwalk, CT (PRWEB) , ... December 07, 2016 ... ... the Integrated Infertility and Wellness (IFW) Program at Reproductive Medicine Associates of Connecticut ... which now has a team of three acupuncturists to help patients realize their ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... 7, 2016  Ionis Pharmaceuticals, Inc. (NASDAQ: IONS ), ... a company overview at the BMO Capital Markets Prescriptions for Success ... NY . A live webcast of the presentation ... Ionis website.  The replay will be available within 48 hours and ... ...
(Date:12/7/2016)... (NYSE: LCI ) today announced that the company will ... Conference on December 14, 2016 at 9:20 a.m. (ET) at the ... In addition, the company will host one-on-one meetings with ... Boston Healthcare Conference taking place on December 13, 2016 at the ... , , ...
(Date:12/6/2016)... -- Alopexx Oncology, LLC announced data from a Phase I ... composed of interleukin-2 and a CD20-targeting monoclonal antibody. The ... as Rituxan and maintains the activities of both the ... tumor targeting, engagement of the immune system, and induction ... study (abstract #95954) were presented at the 58 th ...
Breaking Medicine Technology: